Calidi Biotherapeutics (CLDI) Cash from Investing Activities (2022 - 2025)
Calidi Biotherapeutics (CLDI) posted quarterly Cash from Investing Activities of -$79000.0 for Q4 2025, down 1480.0% year-over-year from $5724.6 in Q4 2024, and down 192.59% quarter-over-quarter from -$27000.0 in Q3 2025.
Calidi Biotherapeutics (CLDI) Cash from Investing Activities (2022 - 2025) Analysis & Trends
Calidi Biotherapeutics' Cash from Investing Activities history runs 4 years deep, the most recent figure standing at -$79000.0 for Q4 2025.
- In Q4 2025, Cash from Investing Activities fell 1480.0% year-over-year to -$79000.0; the TTM figure through Dec 2025 stood at -$170000.0 (down 962.5% YoY), while the FY2025 annual figure was -$170000.0, down 962.5% from the prior year.
- Cash from Investing Activities for Q4 2025 stood at -$79000.0, down from -$27000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was -$5000.0 in Q1 2024, with the low at -$333000.0 in Q3 2022.
- The 4-year median for Cash from Investing Activities is -$57000.0 (2025), against an average of -$89076.9.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities soared 96.35% in 2024, then slumped 1480.0% in 2025.
- Calidi Biotherapeutics' Cash from Investing Activities stood at -$161000.0 in 2022, then soared by 78.26% to -$35000.0 in 2023, then jumped by 85.71% to -$5000.0 in 2024, then plunged by 1480.0% to -$79000.0 in 2025.
- Business Quant data shows CLDI's Cash from Investing Activities at -$79000.0 in Q4 2025, -$27000.0 in Q3 2025, and -$57000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -79,000.00 |
| Dec 31, 2025 | -79,000.00 |
| Sep 30, 2025 | -27,000.00 |
| Sep 30, 2025 | -27,000.00 |
| Jun 30, 2025 | -57,000.00 |
| Jun 30, 2025 | -57,000.00 |
| Mar 31, 2025 | -7,000.00 |
| Mar 31, 2025 | -7,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Sep 30, 2024 | -6,000.00 |
| Sep 30, 2024 | -6,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Dec 31, 2023 | -35,000.00 |
| Dec 31, 2023 | -35,000.00 |
| Sep 30, 2023 | -63,000.00 |
| Sep 30, 2023 | -63,000.00 |
| Jun 30, 2023 | -243,000.00 |
| Jun 30, 2023 | -243,000.00 |